Bias in estimating the causal hazard ratio when using two-stage instrumental variable methods

Stat Med. 2015 Jun 30;34(14):2235-65. doi: 10.1002/sim.6470. Epub 2015 Mar 20.

Abstract

Two-stage instrumental variable methods are commonly used to estimate the causal effects of treatments on survival in the presence of measured and unmeasured confounding. Two-stage residual inclusion (2SRI) has been the method of choice over two-stage predictor substitution (2SPS) in clinical studies. We directly compare the bias in the causal hazard ratio estimated by these two methods. Under a principal stratification framework, we derive a closed-form solution for asymptotic bias of the causal hazard ratio among compliers for both the 2SPS and 2SRI methods when survival time follows the Weibull distribution with random censoring. When there is no unmeasured confounding and no always takers, our analytic results show that 2SRI is generally asymptotically unbiased, but 2SPS is not. However, when there is substantial unmeasured confounding, 2SPS performs better than 2SRI with respect to bias under certain scenarios. We use extensive simulation studies to confirm the analytic results from our closed-form solutions. We apply these two methods to prostate cancer treatment data from Surveillance, Epidemiology and End Results-Medicare and compare these 2SRI and 2SPS estimates with results from two published randomized trials.

Keywords: bias; instrumental variable; survival; two-stage predictor substitution; two-stage residual inclusion; unmeasured confounding.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Bias*
  • Causality
  • Computer Simulation
  • Confounding Factors, Epidemiologic*
  • Evaluation Studies as Topic
  • Humans
  • Likelihood Functions
  • Linear Models
  • Male
  • Medicare / statistics & numerical data
  • Outcome and Process Assessment, Health Care / statistics & numerical data*
  • Probability
  • Proportional Hazards Models
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / mortality*
  • Prostatic Neoplasms / radiotherapy
  • Randomized Controlled Trials as Topic / methods
  • Randomized Controlled Trials as Topic / statistics & numerical data
  • Regression Analysis
  • SEER Program
  • Survival Analysis
  • United States / epidemiology